Tham khảo Patiromer

  1. ↑ Henneman, A; Guirguis, E; Grace, Y; Patel, D; Shah, B (2016). "Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting". American Journal of Health-System Pharmacy. 73 (2): 33–44. doi:10.2146/ajhp150457. PMID 26721532.
  2. 1 2 3 4 5 6 7 8 FDA Professional Drug Information for Veltassa.
  3. ↑ Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, Jeejeebhoy FM, Gabrielli A; Morrison; Shuster; Donnino; Sinz; Lavonas; Jeejeebhoy; Gabrielli (2010-11-02). "Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S829–61. doi:10.1161/CIRCULATIONAHA.110.971069. PMID 20956228.CS1 maint: Multiple names: authors list (link)
  4. 1 2 Esteras, R.; Perez-Gomez, M. V.; Rodriguez-Osorio, L.; Ortiz, A.; Fernandez-Fernandez, B. (2015). "Combination use of medicines from two classes of renin-angiotensin system blocking agents: Risk of hyperkalemia, hypotension, and impaired renal function". Therapeutic Advances in Drug Safety. 6 (4): 166–76. doi:10.1177/2042098615589905. PMC 4530349. PMID 26301070.
  5. ↑ Rastegar, A; Soleimani, M (2001). "Hypokalaemia and hyperkalaemia". Postgraduate Medical Journal. 77 (914): 759–64. doi:10.1136/pmj.77.914.759. PMC 1742191. PMID 11723313.
  6. ↑ Tamargo, J; Caballero, R; Delpón, E (2014). "New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?". Discovery medicine. 18 (100): 249–54. PMID 25425465.
  7. 1 2 "FDA approves new drug to treat hyperkalemia". FDA. ngày 21 tháng 10 năm 2015.
  8. ↑ Pharmabiz: US FDA approves removal of boxed warning on Relypsa's hyperkalemia drug, Veltassa.
  9. ↑ FDA Package Insert: VELTASSA (patiromer) for oral suspension.
  10. 1 2 RxList: Veltassa.
  11. ↑ Weir, Matthew R.; Bakris, George L.; Bushinsky, David A.; Mayo, Martha R.; Garza, Dahlia; Stasiv, Yuri; Wittes, Janet; Christ-Schmidt, Heidi; Berman, Lance; Pitt, Bertram (2015). "Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors". New England Journal of Medicine. 372 (3): 211–21. doi:10.1056/NEJMoa1410853. PMID 25415805.

Tài liệu tham khảo

WikiPedia: Patiromer http://www.drugs.com/veltassa.html http://www.pharmabiz.com/NewsDetails.aspx?aid=9898... http://www.rxlist.com/veltassa-drug.htm http://www.accessdata.fda.gov/drugsatfda_docs/labe... http://www.fda.gov/NewsEvents/Newsroom/PressAnnoun... //pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid... //www.ncbi.nlm.nih.gov/pmc/articles/PMC1742191 //www.ncbi.nlm.nih.gov/pmc/articles/PMC4530349 //www.ncbi.nlm.nih.gov/pubmed/11723313 //www.ncbi.nlm.nih.gov/pubmed/20956228